News from nektar therapeutics A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 01, 2016, 09:00 ET

Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer in Clinical Cancer Research

 Nektar Therapeutics (Nasdaq: NKTR) today announced the publication in Clinical Cancer Research of pre-clinical findings for NKTR-214. The...

Jan 06, 2016, 16:10 ET

Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA

 Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard W. Robin, is scheduled to present at the upcoming...

Dec 21, 2015, 08:26 ET

Baxalta's ADYNOVATE Meets Endpoints in Phase 3 Study of Hemophilia A Patients Under 12 Years of Age

 Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan...

Dec 08, 2015, 16:15 ET

Nektar Therapeutics to Present at Oppenheimer 26th Annual Healthcare Conference in New York

 Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the Oppenheimer 26th...

Dec 08, 2015, 09:00 ET

Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine

 Nektar Therapeutics (NASDAQ:NKTR) today announced that dosing has commenced in the Phase 1/2 clinical study evaluating the efficacy and safety...

Dec 07, 2015, 10:31 ET

Baxalta Presents Additional Data on Newly-Approved ADYNOVATE and Plans for New Indications During 57th American Society of Hematology (ASH) Annual Meeting

 Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan...

Nov 30, 2015, 10:21 ET

Baxalta Announces U.S. Availability of ADYNOVATE, A New Treatment for Adult Patients with Hemophilia A With a Simple, Twice-Weekly Dosing Schedule

Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan...

Nov 17, 2015, 09:00 ET

Nektar Therapeutics to Present at Jefferies Autumn 2015 Global Healthcare Conference in London

 Nektar Therapeutics (Nasdaq: NKTR) today announced that the company will be webcasting its corporate presentation at the Jefferies Autumn 2015...

Nov 16, 2015, 08:00 ET

Baxalta to Advance Care for Hemophilia A patients with FDA Approval of ADYNOVATE, a Simple, Twice-weekly Treatment to Reduce Bleeds

 Baxalta Incorporated (NYSE: BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan...

Nov 05, 2015, 16:15 ET

Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015

Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the third quarter ended September 30, 2015. Cash and investments in...

Oct 29, 2015, 17:38 ET

Nektar to Announce Financial Results for the Third Quarter 2015 on Thursday, November 5, 2015, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter ended September 30, 2015 on Thursday, November 5,...

Oct 08, 2015, 11:29 ET

Nektar Reports on Advancements with Pain and Oncology Clinical Pipeline at Investor and Analyst R&D Day

 Nektar Therapeutics (Nasdaq: NKTR) will present an overview of the Company's pain and oncology portfolio during an Investor and Analyst...

Oct 07, 2015, 08:45 ET

Nektar Submits Investigational New Drug Application (IND) for NKTR-214 To Treat Solid Tumor Malignancies

Nektar Therapeutics (NASDAQ:NKTR) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug...

Oct 06, 2015, 08:45 ET

Nektar Closes Direct Private Placement with TPG Special Situations Partners of $250 Million of Senior Secured Notes Due in 2020

Nektar Therapeutics (Nasdaq: NKTR) today announced the closing of a direct private placement of $250 million of 7.75% Senior Secured Notes Due in...

Oct 01, 2015, 08:45 ET

Nektar to Host Research & Development Day for Analysts and Investors on October 8th

 Nektar Therapeutics (NASDAQ: NKTR) today announced that it will host a Research and Development (R&D) Day for analysts and investors on...

Sep 21, 2015, 09:00 ET
Sep 01, 2015, 08:30 ET

Nektar Announces Receipt of $40 Million Milestone Payment Resulting from First Commercial Sale of MOVENTIG® (naloxegol) Tablets in Major European Market

 Nektar Therapeutics (NASDAQ: NKTR) announced today that it has received a $40 million cash payment under a license agreement with...

Aug 05, 2015, 16:15 ET

Nektar Therapeutics Reports Financial Results for the Second Quarter of 2015

 Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2015. Cash and investments in...

Jul 29, 2015, 17:19 ET

Nektar to Announce Financial Results for the Second Quarter 2015 on Wednesday, August 5, 2015, After Close of U.S.-Based Financial Markets

 Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2015 on Wednesday, August 5,...

Jul 16, 2015, 15:36 ET

Baxalta's BAX 855 Pivotal Data Published in Blood Shows Potential to Provide Strong Bleed Prevention with Twice Weekly Dosing for Patients with Hemophilia A

Nektar Therapeutics (Nasdaq: NKTR) reported that partner Baxalta Incorporated, a global biopharmaceutical leader dedicated to delivering...